Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic Escherichia coli strains.

IF 4.5 2区 医学 Q2 MICROBIOLOGY Antimicrobial Agents and Chemotherapy Pub Date : 2025-05-07 Epub Date: 2025-04-01 DOI:10.1128/aac.01699-24
Tsuyoshi Uehara, Cassandra L Chatwin, Brittany Miller, Mitchell Edwards, Annie Stevenson, Jenna Colombo, David A Six, Denis M Daigle, Greg Moeck, Steven A Boyd, Daniel C Pevear
{"title":"Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic <i>Escherichia coli</i> strains.","authors":"Tsuyoshi Uehara, Cassandra L Chatwin, Brittany Miller, Mitchell Edwards, Annie Stevenson, Jenna Colombo, David A Six, Denis M Daigle, Greg Moeck, Steven A Boyd, Daniel C Pevear","doi":"10.1128/aac.01699-24","DOIUrl":null,"url":null,"abstract":"<p><p>Cefepime-taniborbactam is a β-lactam/β-lactamase inhibitor combination in clinical development for the treatment of Enterobacterales and <i>Pseudomonas</i> infections, including carbapenem-resistant Enterobacterales and multidrug-resistant <i>Pseudomonas aeruginosa</i>. Taniborbactam is a novel cyclic boronate with direct inhibitory activity against clinically relevant Ambler class A, B, C, and D β-lactamases. To further characterize the spectrum of β-lactamase coverage by cefepime-taniborbactam, we constructed 190 isogenic strains of <i>Escherichia coli</i> that constitutively expressed a different β-lactamase. Synthetic codon-optimized genes encoding the mature periplasmic protein linked to the TEM-1 signal sequence were used for optimized expression and periplasmic localization of the β-lactamase. The repertoire of β-lactamases consisted of 50 Ambler class A, 34 class B (metallo), 48 class C, and 58 class D enzymes known to mediate β-lactam resistance in the clinical isolates of Enterobacterales and <i>P. aeruginosa</i>. Overall, in the 190 isogenic strains, the MIC<sub>50</sub>/MIC<sub>90</sub> values were 8/128 µg/mL for cefepime and >128/>128 µg/mL for ceftazidime. Cefepime-taniborbactam (MIC<sub>50</sub>/MIC<sub>90</sub> of 0.25/8 µg/mL) showed greater activity than ceftazidime-avibactam (MIC<sub>50</sub>/MIC<sub>90</sub> of 4/>128 µg/mL) and similar activity to aztreonam-avibactam (MIC<sub>50</sub>/MIC<sub>90</sub> of 0.5/4 µg/mL). Cefepime-taniborbactam inhibited strains overproducing metallo-β-lactamases, including clinically important NDM and VIM enzymes, whereas ceftazidime-avibactam showed no coverage. Among the 129 β-lactamase-overproducing strains with increased cefepime MIC ≥16-fold relative to the control strain, taniborbactam potentiated cefepime MIC by ≥8-fold for 113 strains overexpressing β-lactamases (42 Ambler class A, 24 B, 23 C, and 24 D). Cefepime-taniborbactam demonstrated broader activity relative to ceftazidime-avibactam and comparable activity with aztreonam-avibactam in the overall coverage of both serine- and metallo-β-lactamases from all four Ambler classes.</p>","PeriodicalId":8152,"journal":{"name":"Antimicrobial Agents and Chemotherapy","volume":" ","pages":"e0169924"},"PeriodicalIF":4.5000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057355/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antimicrobial Agents and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1128/aac.01699-24","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Cefepime-taniborbactam is a β-lactam/β-lactamase inhibitor combination in clinical development for the treatment of Enterobacterales and Pseudomonas infections, including carbapenem-resistant Enterobacterales and multidrug-resistant Pseudomonas aeruginosa. Taniborbactam is a novel cyclic boronate with direct inhibitory activity against clinically relevant Ambler class A, B, C, and D β-lactamases. To further characterize the spectrum of β-lactamase coverage by cefepime-taniborbactam, we constructed 190 isogenic strains of Escherichia coli that constitutively expressed a different β-lactamase. Synthetic codon-optimized genes encoding the mature periplasmic protein linked to the TEM-1 signal sequence were used for optimized expression and periplasmic localization of the β-lactamase. The repertoire of β-lactamases consisted of 50 Ambler class A, 34 class B (metallo), 48 class C, and 58 class D enzymes known to mediate β-lactam resistance in the clinical isolates of Enterobacterales and P. aeruginosa. Overall, in the 190 isogenic strains, the MIC50/MIC90 values were 8/128 µg/mL for cefepime and >128/>128 µg/mL for ceftazidime. Cefepime-taniborbactam (MIC50/MIC90 of 0.25/8 µg/mL) showed greater activity than ceftazidime-avibactam (MIC50/MIC90 of 4/>128 µg/mL) and similar activity to aztreonam-avibactam (MIC50/MIC90 of 0.5/4 µg/mL). Cefepime-taniborbactam inhibited strains overproducing metallo-β-lactamases, including clinically important NDM and VIM enzymes, whereas ceftazidime-avibactam showed no coverage. Among the 129 β-lactamase-overproducing strains with increased cefepime MIC ≥16-fold relative to the control strain, taniborbactam potentiated cefepime MIC by ≥8-fold for 113 strains overexpressing β-lactamases (42 Ambler class A, 24 B, 23 C, and 24 D). Cefepime-taniborbactam demonstrated broader activity relative to ceftazidime-avibactam and comparable activity with aztreonam-avibactam in the overall coverage of both serine- and metallo-β-lactamases from all four Ambler classes.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
头孢吡肟-taniborbactam对工程等基因大肠杆菌菌株中190种β-内酰胺酶的覆盖谱。
头孢吡肟-他尼巴坦是一种β-内酰胺/β-内酰胺酶抑制剂复方制剂,目前正处于临床开发阶段,用于治疗肠杆菌和假单胞菌感染,包括耐碳青霉烯类肠杆菌和耐多药铜绿假单胞菌。他尼巴坦是一种新型环硼酸盐,对临床相关的安布勒 A、B、C 和 D 类 β-内酰胺酶具有直接抑制活性。为了进一步确定头孢吡肟-他尼巴坦对 β-内酰胺酶的覆盖范围,我们构建了 190 株组成型表达不同 β-内酰胺酶的大肠杆菌异源菌株。编码与 TEM-1 信号序列相连的成熟周质蛋白的合成密码子优化基因被用于优化 β-内酰胺酶的表达和周质定位。β-内酰胺酶谱包括 50 种安布勒 A 类、34 种 B 类(金属)、48 种 C 类和 58 种 D 类酶,已知这些酶介导了肠杆菌属和铜绿假单胞菌临床分离物对β-内酰胺的耐药性。总体而言,在 190 株同源菌株中,头孢吡肟的 MIC50/MIC90 值为 8/128 µg/mL ,头孢他啶的 MIC50/MIC90 值>128/>128 µg/mL。头孢吡肟-他尼巴坦(MIC50/MIC90 为 0.25/8 µg/mL)比头孢唑肟-阿维巴坦(MIC50/MIC90 为 4/>128 µg/mL)显示出更强的活性,而与阿兹曲南-阿维巴坦(MIC50/MIC90 为 0.5/4 µg/mL)的活性相似。头孢吡肟-他尼巴坦可抑制过度产生金属-β-内酰胺酶的菌株,包括临床上重要的 NDM 和 VIM 酶,而头孢唑肟-阿维巴坦则没有覆盖范围。与对照菌株相比,在头孢吡肟 MIC 增加≥16 倍的 129 株过度产生β-内酰胺酶的菌株中,对于 113 株过度表达β-内酰胺酶的菌株(42 株 Ambler A 级、24 株 B 级、23 株 C 级和 24 株 D 级),他尼巴坦可使头孢吡肟 MIC 增效≥8 倍。头孢吡肟-他尼巴坦与头孢唑肟-阿维巴坦相比具有更广泛的活性,而在对所有四个安布勒类的丝氨酸和金属-β-内酰胺酶的总体覆盖范围内,头孢吡肟-他尼巴坦的活性与阿兹曲南-阿维巴坦相当。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
10.00
自引率
8.20%
发文量
762
审稿时长
3 months
期刊介绍: Antimicrobial Agents and Chemotherapy (AAC) features interdisciplinary studies that build our understanding of the underlying mechanisms and therapeutic applications of antimicrobial and antiparasitic agents and chemotherapy.
期刊最新文献
Peroxin Pex8 couples stress responses, antifungal tolerance, and virulence regulation in Candida albicans. Identification and characteristics of a novel acquired aminoglycoside phosphotransferase, APH(3')-IVb, from Riemerella anatipestifer. Benzoxaborole-modified azithromycins inhibit translation without inducing ermC expression. Piperacillin-tazobactam resistance in Klebsiella pneumoniae is often associated with IS26-mediated blaSHV-1 amplification in a widespread Klebsiella-adapted plasmid. Comparative in vitro activity of aztreonam-avibactam and aztreonam plus ceftazidime-avibactam against Stenotrophomonas maltophilia complex.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1